3-(Imidazolyl methyl)-3-aza-bicyclo[3.1.0]hexan-6-yl)methyl ethers: A novel series of mGluR2 positive allosteric modulators

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 20, 2008, Pages 5493-5496

  Zhang, Lei ^a   Rogers, Bruce N ^a   Duplantier, Allen J ^a   McHardy, Stanley F ^a   Efremov, Ivan ^a   Berke, Helen ^a   Qian, Weimin ^a   Zhang, Andy Q ^a   Maklad, Noha ^a   Candler, John ^a   Doran, Angela C ^a   Lazzaro Jr , John T ^a   Ganong, Alan H ^a  

^a PFIZER INC   (United States)

Author keywords

Anxiety; mGluR2; Positive allosteric modulators; Potentiators; Schizophrenia

Indexed keywords

3 (IMIDAZOLYLMETHYL) 3 AZABICYCLO[3.1.0]HEXAN 6 YLMETHYL ETHER DERIVATIVE; BICYCLO COMPOUND; IMIDAZOLE DERIVATIVE; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL EXPERIMENT; ARTICLE; DRUG BIOAVAILABILITY; DRUG IDENTIFICATION; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; NONHUMAN; PROCESS OPTIMIZATION; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; AZABICYCLO COMPOUNDS; BENZIMIDAZOLES; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ETHERS; HUMANS; MICROSOMES; MODELS, CHEMICAL; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 53349165547     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.09.026     Document Type: Article

References (19)

1. Pellicciari R., and Constantino G. Curr. Opin. Chem. Biol. 3 (1999) 433
2. Conn P.J., and Pin J.-P. Annu. Rev. Pharmocol. Toxicol. 37 (1997) 205
3. Levine L., Gaydos B., Sheehan D., Goddard A.W., Feighner J., Potter W.Z., and Schoepp D.D. Neuropharmacology 43 (2002) 294
4. Spooren W.P.J.M., Gasparini F., van der Putten H., Koller M., Nakanichi S., and Kuhn R. Eur. J. Pharmacol. 397 (2000) R1
5. Klodzinska A., Chojnacka-Wojcik E., and Pilc A. Pol. J. Pharmacol. 51 (1999) 543
6. Kinoeczny J., Ossowaska K., Wolfarth S., and Pilc A. Nauyn-Schmiedeberg's Arch. Pharmacol. 358 (1998) 500
7. Kingston A.E., O'Neill M.J., Lam A., Bales K.R., Monn J.A., and Schoepp D.D. Eur. J. Phamacol. 377 (1999) 155
8. Jones C.K., Eberle E.L., Peters S.C., Monn J.A., and Shannon H.E. Neuropharmacology 49 (2005) 206
9. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., and Schoepp D.D. Nat. Med. 13 (2007) 1102
10. For a recent review, see:. Recasens M., Guiramand J., Aimar R., Abdulkarium A., and Barbanel G. Curr. Drug Targets 8 (2007) 651
11. For recent reviews, see:. Gasparini F., and Spooren W. Curr. Neuropharmacol. 5 (2007) 187
12. Rudd M.T., and McCauley J.A. Curr. Top. Med. Chem. 5 (2005) 869
13. 20 glutamate challenge. Data is analyzed as a ratio of the peak fluorescence to the baseline after compound addition. Assay to assay variability in PAM potency required multiple experiments to determine potency, typically n > 3.
14. Whole brain and blood samples were collected from Sprague-Dawley rats at various times following administration of a single 10 mg/kg subcutaneous dose. Plasma and brain homogenate samples were quantitated using an LC/MS method and the brain to plasma ratio reported.
15. Compound 1 (1 μM) was incubated in rat or human liver microsome and monitored for substrate depletion using an LC/MS method. Hepatic clearance was determined by scaling of the observed half-life using the well stirred model.
16. Pharmacokinetic parameters were determined in rats following a 1 mg/kg intravenous or 5 mg/kg oral administration to male Sprague-Dawley rats. Whole blood was collected from a jugular (iv and oral) or portal vein (oral only) catheter and plasma samples analyzed using an LC/MS method. Pharmacokinetic parameters were calculated using a non-compartmental analysis of the plasma concentration versus time data.
17. Brighty K.E., and Castaldi M.J. Synlett 11 (1996) 1097
18. Kwon Y. Pharmacol. Res. 13 (1996) 566
19. In vitro rat microsomal stability r-CLh of 14c is 41 ml/min/kg, consistent with the in vivo measurement (within two folds).